February 23, 2017 10:48 AM ET

Biotechnology

Company Overview of Immune Design Corp.

Company Overview

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. It develops various product candidates based on its ZVex and GLAAS product discovery platforms. The company’s products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are ...

1616 Eastlake Avenue East

Suite 310

Seattle, WA 98102

United States

Founded in 2008

41 Employees

Phone:

206-682-0645

Fax:

206-682-0648

Key Executives for Immune Design Corp.

Chief Executive Officer, President and Director
Age: 57
Total Annual Compensation: $530.5K
Principal Financial Officer, Principal Accounting Officer and Executive Vice President of Strategy & Finance
Age: 46
Total Annual Compensation: $331.0K
Compensation as of Fiscal Year 2015.

Immune Design Corp. Key Developments

Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate

Immune Design announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational intratumoral therapy, G100, for the treatment of follicular non-Hodgkin’s lymphoma.  Orphan Drug Designation is granted by the FDA Office of Orphan Drug Products to products that treat rare diseases. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity for the first marketing application, if regulatory approval is received for the designated indication, potential tax credits for certain activities and waiver of certain administrative fees. G100 is a product candidate from Immune Design's GLAAS® discovery platform. It contains a potent synthetic small molecule toll-like receptor-4 (TLR-4) agonist, Glucopyranosyl Lipid A (GLA), and is the lead product candidate in Immune Design’s Antigen Agnostic approach. It leverages the activation of both innate and adaptive immunity, including Dendritic Cells, in the tumor microenvironment to create an immune response against the tumor's preexisting diverse set of antigens. A growing set of clinical and preclinical data have demonstrated the ability of G100 to activate tumor-infiltrating lymphocytes, macrophages and dendritic cells, and promote antigen-presentation and the recruitment of T cells to the tumor.

Immune Design Corp. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 10:30 AM

Immune Design Corp. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 10:30 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York, New York, United States. Speakers: Carlos V. Paya, Chief Executive Officer, President and Director.

Richard Kenney Resigns as Principal Medical Advisor of Immune Design Corp

On December 16, 2016, Richard Kenney, M.D. resigned as Principal Medical Advisor of Immune Design Corp.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Immune Design Corp., please visit www.immunedesign.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.